Author Interviews, Cannabis, JAMA, UCSD / 23.10.2019
Online Searches for CBD Skyrocket
MedicalResearch.com Interview with:
[caption id="attachment_51918" align="alignleft" width="158"]
Dr. Ayers[/caption]
John W. Ayers, PhD, MA
Vice Chief of Innovation | Assoc. Professor
Div. Infectious Disease & Global Public Health
University of California San Diego
MedicalResearch.com: What is the background for this study?
Response: Touted as a “cure all,” researchers have documented unfounded claims
that cannabidiol (CBD) treats acne, anxiety, opioid addiction, pain,
and menstrual problems. You can buy CBD droplets, massage oils,
CBD gummies, or even ice cream.
But public health leaders have been mostly silent on the subject because they lacked data
that demonstrates just how popular CBD is and the future trajectory might be.
To fill this data-gap we analyzed Google search queries that mentioned
“CBD” or “cannabidiol” emerging from the United States from January
2004 through April 2019 and forecasted searches through December 2019.
Rather than relying on self reports, where some might not be willing
to discuss CBD openly, our strategy allowed us to directly observed
millions of instances of people seeking out information or even
shopping for CBD online.
Dr. Ayers[/caption]
John W. Ayers, PhD, MA
Vice Chief of Innovation | Assoc. Professor
Div. Infectious Disease & Global Public Health
University of California San Diego
MedicalResearch.com: What is the background for this study?
Response: Touted as a “cure all,” researchers have documented unfounded claims
that cannabidiol (CBD) treats acne, anxiety, opioid addiction, pain,
and menstrual problems. You can buy CBD droplets, massage oils,
CBD gummies, or even ice cream.
But public health leaders have been mostly silent on the subject because they lacked data
that demonstrates just how popular CBD is and the future trajectory might be.
To fill this data-gap we analyzed Google search queries that mentioned
“CBD” or “cannabidiol” emerging from the United States from January
2004 through April 2019 and forecasted searches through December 2019.
Rather than relying on self reports, where some might not be willing
to discuss CBD openly, our strategy allowed us to directly observed
millions of instances of people seeking out information or even
shopping for CBD online.
Ruibin Lu
Assistant Professor of Criminal Justice
Stockton University
Absecon, New Jersey
MedicalResearch.com: What is the background for this study?
Response: We are witnessing a trend of legalizing marijuana in the United States and in the world. Many states have either legalized recreational marijuana or are considering it. At the same time, there are concerns about what will happen to our society if weed is legal. One of the concerns is about crime rates: are we going to experience more or fewer crimes after legalizing recreational marijuana? This is a legitimate question that we should consider when making cannabis-related public policies. Our research provides a preliminary answer to this question. It analyzes crime rates before and after the legalization using rigorous scientific methods and provides more information on how marijuana legalization may affect crime rates.
Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
MedicalResearch.com: What is the background for this study?
Response: Although marijuana is still classified as a Schedule I drug at the Federal level, as of June 2019, 33 states and the District of Columbia have legalized one or more forms of marijuana; 11 states and the District of Columbia have approved both medical and recreational uses. Public opinion on marijuana has changed dramatically over the last two decades and support for legalization has doubled since 2010. However, very little is known about the prevalence and patterns of marijuana use among adults with medical conditions.
This study analyzed the 2016 and 2017 Behavioral Risk Factor Surveillance System data to report the prevalence and patterns of marijuana use among adults with self-reported medical conditions.


Dr. Gery Guy[/caption]
Gery P. Guy Jr., PhD, MPH
Senior Health Economist
Division of Unintentional Injury Prevention
CDC
MedicalResearch.com: What is the background for this study?
Response: In 2017, among the 70,237 drug overdose deaths in the United States, 47,600 (67.8%) involved prescription or illicit opioids. Distribution of the opioid receptor antagonist naloxone to reverse overdose is a key part of the public health response to the opioid overdose epidemic. The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommended clinicians consider offering naloxone when overdose risk factors, such as history of overdose or opioid use disorder, higher opioid dosages, or concurrent benzodiazepine use, are present.
However, recent analyses examining pharmacy-based naloxone dispensing are lacking. To address this gap and to inform future overdose prevention and response efforts, CDC examined trends and characteristics of naloxone dispensed from retail pharmacies at the national and county level in the United States.
